Bronfman E.L. Rothschild L.P. lowered its position in Novo Nordisk A/S (NYSE:NVO) by 5.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,671 shares of the company’s stock after selling 1,478 shares during the quarter. Bronfman E.L. Rothschild L.P.’s holdings in Novo Nordisk A/S were worth $1,091,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently modified their holdings of NVO. Bruderman Asset Management LLC purchased a new stake in shares of Novo Nordisk A/S during the fourth quarter valued at approximately $29,000. Karp Capital Management Corp purchased a new stake in shares of Novo Nordisk A/S during the fourth quarter valued at approximately $43,000. We Are One Seven LLC purchased a new stake in shares of Novo Nordisk A/S during the fourth quarter valued at approximately $46,000. Highwater Wealth Management LLC purchased a new stake in shares of Novo Nordisk A/S during the fourth quarter valued at approximately $49,000. Finally, Berman Capital Advisors LLC purchased a new stake in shares of Novo Nordisk A/S during the fourth quarter valued at approximately $49,000. 7.08% of the stock is owned by institutional investors and hedge funds.

A number of analysts have recently weighed in on NVO shares. Zacks Investment Research lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Thursday, January 24th. UBS Group reissued a “buy” rating on shares of Novo Nordisk A/S in a research note on Monday, November 26th. Barclays reissued a “sell” rating on shares of Novo Nordisk A/S in a research note on Tuesday, February 5th. HSBC reissued a “sell” rating on shares of Novo Nordisk A/S in a research note on Monday, November 26th. Finally, Morgan Stanley initiated coverage on Novo Nordisk A/S in a research note on Friday, February 1st. They issued an “equal weight” rating for the company. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and seven have issued a buy rating to the company. Novo Nordisk A/S presently has a consensus rating of “Hold” and a consensus price target of $52.31.

Shares of NVO stock opened at $50.89 on Friday. Novo Nordisk A/S has a 52 week low of $41.23 and a 52 week high of $51.64. The firm has a market capitalization of $124.35 billion, a P/E ratio of 20.19, a price-to-earnings-growth ratio of 2.33 and a beta of 0.59.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Friday, February 1st. The company reported $0.54 EPS for the quarter, missing analysts’ consensus estimates of $0.57 by ($0.03). Novo Nordisk A/S had a return on equity of 80.45% and a net margin of 34.67%. The business had revenue of $4.55 billion during the quarter, compared to analysts’ expectations of $4.36 billion. As a group, analysts expect that Novo Nordisk A/S will post 2.58 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This piece was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another site, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this piece can be viewed at https://www.watchlistnews.com/bronfman-e-l-rothschild-l-p-cuts-holdings-in-novo-nordisk-a-s-nvo/2896869.html.

About Novo Nordisk A/S

Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases.

See Also: What is a Reverse Stock Split?

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.